Invivyd

Invivyd

Field Reimbursement Manager, Southwest

Remote (San Diego, Phoenix, El Paso or Denver) · Full-time

Sponsorship not specified$152k-$202kDetected 1 day ago
CRMAccount ManagementPatient CareFDA RegulatoryPublic Speaking

About the role

  • The FRM ensures a positive customer experience by delivering clear guidance, resolving issues efficiently, and supporting timely and appropriate patient access to therapy.

Responsibilities

  • Leverage market insights to anticipate customer needs and develop strategies that maintain a competitive edge.
  • At Invivyd we strive to create a welcoming and inclusive environment.

Requirements

  • Proven track record of success, meeting or exceeding business KPIs.
  • Working knowledge of the formulary inclusion process and familiarity with sub-committees.
  • Analytical mindset with the ability to interpret sales data, market trends, and customer insights.
  • Experience working in CRM systems and sales analytics tools.

Nice to have

  • Bachelor's degree strongly preferred
  • candidates without a degree with significant relevant, related industry experience will be considered

Compensation

  • $152,000 - $202,000
  • The pay range represents the expected full-time base salary for this role at the time of posting.
  • Actual base pay will be determined based on a variety of factors, including relevant experience, skills, and education.
  • In addition to base pay, this role is eligible for both an annual short-term incentive (e.g., bonus or sales incentive) and an annual long-term incentive (e.g., equity), reflecting our commitment to rewarding strong performance and long-term impact.

Benefits

  • Proactively address patient access barriers by working with customers and accounts to resolve complex reimbursement issues, including prior authorizations, appeals, and denials.
  • Educate private practices, multi-specialty groups, facilities, and their staff on reimbursement support programs, coverage, coding, and payer policies.
  • Accountable for ensuring access barriers are minimized, for appropriate patients, to obtain Invivyd products through HCP education.
  • Have a thorough understanding of payor policies and navigating the coverage landscape.
  • Deliver clear and actionable information to practice managers, billing staff, nurses, and reimbursement teams to improve their understanding of payer policies and processes.
  • Conduct regular reviews with practices to understand their utilization of reimbursement support services and recommend program enhancements based on customer needs.
  • Have a deep understanding of coverage pathways to access, for both medical and pharmacy benefit products
  • Have a deep understanding of the Medicare reimbursement landscape.
  • Provide expertise within the national/regional payor landscape in order to educate providers on navigating the reimbursement process and payer trends.
  • Provide training to healthcare professionals on the drug reimbursement process, coding, and billing practices.
  • Navigate and manage access and reimbursement concerns by pulling in the appropriate Invivyd stakeholder.
  • Stay informed about relevant business trends, competitive landscape, regulatory changes, and healthcare policy developments that may impact our customers.

Company info

  • There are more than 9 million immunocompromised people in the United States. Almost half a million of those represent a population that are moderately to severely immunocompromised and at highest risk for severe COVID-19, including stem cell and solid organ transplant patients as well as those with hematologic cancers.
  • At Invivyd, Inc., we take those numbers very seriously and we come to work each day on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.
  • In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates.
  • In October 2025, the FDA cleared the company's Investigational New Drug (IND) application and provided feedback to advance the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine alternative monoclonal antibody being investigated for the prevention of COVID-19.
  • Be part of making a difference.
  • There are more than 9 million immunocompromised people in the United States.
  • Almost half a million of those represent a population that are moderately to severely immunocompromised and at highest risk for severe COVID-19, including stem cell and solid organ transplant patients as well as those with hematologic cancers.
  • At Invivyd, Inc., we take those numbers very seriously and we come to work each day on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2.
  • Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.
  • Be part of Invivyd.
  • San Diego, Phoenix, Denver, El Paso

Equal opportunity

  • Invivyd is proud to be an equal opportunity employer.
Apply directly at Invivyd →Create a free account for alerts like thisView Invivyd immigration profile

This listing is sourced directly from Invivyd's careers page and normalized into a canonical job model.